Dan McKay

Biotechnology and pharmaceutical groups are racing to analyze whether a new U.S. Department of Justice proposal to restrict data-sharing with China and five other countries will disrupt medical research and drug development.

Biotechnology and pharmaceutical groups are racing to analyze whether a new U.S. Department of Justice proposal to restrict data-sharing with China and five other countries will disrupt medical research and drug development.

Biotechnology and pharmaceutical groups are racing to analyze whether a new U.S. Department of Justice proposal to restrict data-sharing with China and five other countries will disrupt medical research and drug development.

Biotechnology and pharmaceutical groups are racing to analyze whether a new U.S. Department of Justice proposal to restrict data-sharing with China and five other countries will disrupt medical research and drug development.

NC Justices Scrutinize Scope Of Liability Shield In COVID Law

A federal agency's unusual flip-flop this month on whether to allow copycat versions of a lucrative weight-loss and diabetes drug may cause regulators to move more cautiously as they weigh how to handle future drug shortages.

A vape store's lawsuit against the U.S. Food and Drug Administration may provide an early look at how judges will apply this year's landmark Supreme Court decision limiting the power of administrative courts to levy civil monetary penalties.

Johnson & Johnson abandoned its plan Monday to offer rebates rather than upfront discounts for two medications under the 340B drug pricing law, contending it had no choice after a federal agency threatened to impose excessive penalties.

New federal guidance may encourage drug and medical device companies to carry out more of their research in decentralized, remote clinical trials, allowing them to enroll a more diverse set of participants but generating new legal questions.

Johnson & Johnson's plan to abandon upfront discounts and instead offer rebates for two popular medications under the 340B drug pricing law would fundamentally alter how the program has worked for decades. Federal enforcement efforts and other legal clashes are likely.